C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes
Background A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults. Methods A total of 4937 di...
Gespeichert in:
| Veröffentlicht in: | Diabetes/metabolism research and reviews 2020-02, Vol.36 (2), p.e3210-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e3210 |
| container_title | Diabetes/metabolism research and reviews |
| container_volume | 36 |
| creator | Wang, Ningjian Wang, Yuying Zhang, Wen Chen, Yi Chen, Xiaoman Wang, Chiyu Li, Qing Chen, Chi Jiang, Boren Lu, Yingli |
| description | Background
A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults.
Methods
A total of 4937 diabetic participants were enrolled from China in 2018. Liver steatosis was detected by ultrasound. Subjects with NAFLD were categorized into simple NAFLD and probable NASH by the concurrent presence of metabolic syndrome. NAFLD fibrosis score was used to identify patients with probable advanced fibrosis.
Results
Individuals with a longer history of type 2 diabetes had a lower C‐peptide level and a lower prevalence of probable NASH but a higher prevalence of advanced fibrosis. C‐peptide was positively associated with simple NAFLD and probable NASH, with odds ratios (ORs) of 4.55 [95% confidence interval (CI) 3.16, 6.55] and 5.28 (95% CI 3.94, 7.09), respectively, comparing quartile 4 with quartile 1 (both p for trend |
| doi_str_mv | 10.1002/dmrr.3210 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2265762597</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2350162368</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3530-4016b5941e4edbb744c534209da6faa2e394513f47d6b51dcf1651bc8f7eed333</originalsourceid><addsrcrecordid>eNp10M1KAzEUBeAgiq3VhS8gATe6aM3vTLssrVWhKhRdSshM7mjK_JlMKd35CD6jT2JqaxeCq3sXH4fDQeiUkh4lhF2ZwrkeZ5TsoTaVjHRjGZH93S9ZCx15PyeEcBGJQ9TilEtKGG2jl9HXx2cNdWMNYOux9r5KrW7A4KVt3vDDcDIdY1tmuS4K3VRuhXVpcGYTVzU2xbWrXh14b6syKNysasAMG6sTaMAfo4NM5x5OtreDnifXT6Pb7vTx5m40nHZTLjnpCkKjRA4EBQEmSWIhUskFIwOjo0xrBnwgJOWZiE1w1KQZjSRN0n4WAxjOeQddbHJDnfcF-EYV1qeQ57qEauEVY5GMIyYHcaDnf-i8WrgytFOMy1CE8agf1OVGpa7y3kGmamcL7VaKErXeXK03V-vNgz3bJi6SAsxO_o4cwNUGLG0Oq_-T1Ph-NvuJ_AaoVot1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350162368</pqid></control><display><type>article</type><title>C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes</title><source>Access via Wiley Online Library</source><creator>Wang, Ningjian ; Wang, Yuying ; Zhang, Wen ; Chen, Yi ; Chen, Xiaoman ; Wang, Chiyu ; Li, Qing ; Chen, Chi ; Jiang, Boren ; Lu, Yingli</creator><creatorcontrib>Wang, Ningjian ; Wang, Yuying ; Zhang, Wen ; Chen, Yi ; Chen, Xiaoman ; Wang, Chiyu ; Li, Qing ; Chen, Chi ; Jiang, Boren ; Lu, Yingli</creatorcontrib><description>Background
A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults.
Methods
A total of 4937 diabetic participants were enrolled from China in 2018. Liver steatosis was detected by ultrasound. Subjects with NAFLD were categorized into simple NAFLD and probable NASH by the concurrent presence of metabolic syndrome. NAFLD fibrosis score was used to identify patients with probable advanced fibrosis.
Results
Individuals with a longer history of type 2 diabetes had a lower C‐peptide level and a lower prevalence of probable NASH but a higher prevalence of advanced fibrosis. C‐peptide was positively associated with simple NAFLD and probable NASH, with odds ratios (ORs) of 4.55 [95% confidence interval (CI) 3.16, 6.55] and 5.28 (95% CI 3.94, 7.09), respectively, comparing quartile 4 with quartile 1 (both p for trend <0.001). However, C‐peptide quartiles were negatively associated with the probable presence of advanced fibrosis (Q4 vs. Q1, OR 0.59, 95% CI 0.36, 0.97, p for trend <0.05). A 1‐SD increment of ln(C‐peptide) was also significantly associated with inflammatory and fibrotic progression (OR 1.34, 95% CI 1.27, 1.41; OR 0.88, 95% CI 0.79, 0.98, respectively).
Conclusions
Significant but opposite associations between C‐peptide and inflammatory and fibrotic progression of NAFLD were observed. Understanding islet hormone changes during type 2 diabetes and differentiating the stage of NAFLD may help to personalize treatment strategies for NAFLD patients with type 2 diabetes.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.3210</identifier><identifier>PMID: 31351021</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>advanced fibrosis ; C‐peptide ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Fatty liver ; Fibrosis ; Inflammation ; Liver diseases ; Metabolic syndrome ; nonalcoholic fatty liver disease ; Peptides ; Steatosis ; type 2 diabetes mellitus ; Ultrasound</subject><ispartof>Diabetes/metabolism research and reviews, 2020-02, Vol.36 (2), p.e3210-n/a</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><rights>2020 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3530-4016b5941e4edbb744c534209da6faa2e394513f47d6b51dcf1651bc8f7eed333</citedby><cites>FETCH-LOGICAL-c3530-4016b5941e4edbb744c534209da6faa2e394513f47d6b51dcf1651bc8f7eed333</cites><orcidid>0000-0002-5117-1614</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.3210$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.3210$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31351021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ningjian</creatorcontrib><creatorcontrib>Wang, Yuying</creatorcontrib><creatorcontrib>Zhang, Wen</creatorcontrib><creatorcontrib>Chen, Yi</creatorcontrib><creatorcontrib>Chen, Xiaoman</creatorcontrib><creatorcontrib>Wang, Chiyu</creatorcontrib><creatorcontrib>Li, Qing</creatorcontrib><creatorcontrib>Chen, Chi</creatorcontrib><creatorcontrib>Jiang, Boren</creatorcontrib><creatorcontrib>Lu, Yingli</creatorcontrib><title>C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab Res Rev</addtitle><description>Background
A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults.
Methods
A total of 4937 diabetic participants were enrolled from China in 2018. Liver steatosis was detected by ultrasound. Subjects with NAFLD were categorized into simple NAFLD and probable NASH by the concurrent presence of metabolic syndrome. NAFLD fibrosis score was used to identify patients with probable advanced fibrosis.
Results
Individuals with a longer history of type 2 diabetes had a lower C‐peptide level and a lower prevalence of probable NASH but a higher prevalence of advanced fibrosis. C‐peptide was positively associated with simple NAFLD and probable NASH, with odds ratios (ORs) of 4.55 [95% confidence interval (CI) 3.16, 6.55] and 5.28 (95% CI 3.94, 7.09), respectively, comparing quartile 4 with quartile 1 (both p for trend <0.001). However, C‐peptide quartiles were negatively associated with the probable presence of advanced fibrosis (Q4 vs. Q1, OR 0.59, 95% CI 0.36, 0.97, p for trend <0.05). A 1‐SD increment of ln(C‐peptide) was also significantly associated with inflammatory and fibrotic progression (OR 1.34, 95% CI 1.27, 1.41; OR 0.88, 95% CI 0.79, 0.98, respectively).
Conclusions
Significant but opposite associations between C‐peptide and inflammatory and fibrotic progression of NAFLD were observed. Understanding islet hormone changes during type 2 diabetes and differentiating the stage of NAFLD may help to personalize treatment strategies for NAFLD patients with type 2 diabetes.</description><subject>advanced fibrosis</subject><subject>C‐peptide</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Fatty liver</subject><subject>Fibrosis</subject><subject>Inflammation</subject><subject>Liver diseases</subject><subject>Metabolic syndrome</subject><subject>nonalcoholic fatty liver disease</subject><subject>Peptides</subject><subject>Steatosis</subject><subject>type 2 diabetes mellitus</subject><subject>Ultrasound</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp10M1KAzEUBeAgiq3VhS8gATe6aM3vTLssrVWhKhRdSshM7mjK_JlMKd35CD6jT2JqaxeCq3sXH4fDQeiUkh4lhF2ZwrkeZ5TsoTaVjHRjGZH93S9ZCx15PyeEcBGJQ9TilEtKGG2jl9HXx2cNdWMNYOux9r5KrW7A4KVt3vDDcDIdY1tmuS4K3VRuhXVpcGYTVzU2xbWrXh14b6syKNysasAMG6sTaMAfo4NM5x5OtreDnifXT6Pb7vTx5m40nHZTLjnpCkKjRA4EBQEmSWIhUskFIwOjo0xrBnwgJOWZiE1w1KQZjSRN0n4WAxjOeQddbHJDnfcF-EYV1qeQ57qEauEVY5GMIyYHcaDnf-i8WrgytFOMy1CE8agf1OVGpa7y3kGmamcL7VaKErXeXK03V-vNgz3bJi6SAsxO_o4cwNUGLG0Oq_-T1Ph-NvuJ_AaoVot1</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Wang, Ningjian</creator><creator>Wang, Yuying</creator><creator>Zhang, Wen</creator><creator>Chen, Yi</creator><creator>Chen, Xiaoman</creator><creator>Wang, Chiyu</creator><creator>Li, Qing</creator><creator>Chen, Chi</creator><creator>Jiang, Boren</creator><creator>Lu, Yingli</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5117-1614</orcidid></search><sort><creationdate>202002</creationdate><title>C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes</title><author>Wang, Ningjian ; Wang, Yuying ; Zhang, Wen ; Chen, Yi ; Chen, Xiaoman ; Wang, Chiyu ; Li, Qing ; Chen, Chi ; Jiang, Boren ; Lu, Yingli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3530-4016b5941e4edbb744c534209da6faa2e394513f47d6b51dcf1651bc8f7eed333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>advanced fibrosis</topic><topic>C‐peptide</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Fatty liver</topic><topic>Fibrosis</topic><topic>Inflammation</topic><topic>Liver diseases</topic><topic>Metabolic syndrome</topic><topic>nonalcoholic fatty liver disease</topic><topic>Peptides</topic><topic>Steatosis</topic><topic>type 2 diabetes mellitus</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ningjian</creatorcontrib><creatorcontrib>Wang, Yuying</creatorcontrib><creatorcontrib>Zhang, Wen</creatorcontrib><creatorcontrib>Chen, Yi</creatorcontrib><creatorcontrib>Chen, Xiaoman</creatorcontrib><creatorcontrib>Wang, Chiyu</creatorcontrib><creatorcontrib>Li, Qing</creatorcontrib><creatorcontrib>Chen, Chi</creatorcontrib><creatorcontrib>Jiang, Boren</creatorcontrib><creatorcontrib>Lu, Yingli</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ningjian</au><au>Wang, Yuying</au><au>Zhang, Wen</au><au>Chen, Yi</au><au>Chen, Xiaoman</au><au>Wang, Chiyu</au><au>Li, Qing</au><au>Chen, Chi</au><au>Jiang, Boren</au><au>Lu, Yingli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab Res Rev</addtitle><date>2020-02</date><risdate>2020</risdate><volume>36</volume><issue>2</issue><spage>e3210</spage><epage>n/a</epage><pages>e3210-n/a</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><abstract>Background
A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults.
Methods
A total of 4937 diabetic participants were enrolled from China in 2018. Liver steatosis was detected by ultrasound. Subjects with NAFLD were categorized into simple NAFLD and probable NASH by the concurrent presence of metabolic syndrome. NAFLD fibrosis score was used to identify patients with probable advanced fibrosis.
Results
Individuals with a longer history of type 2 diabetes had a lower C‐peptide level and a lower prevalence of probable NASH but a higher prevalence of advanced fibrosis. C‐peptide was positively associated with simple NAFLD and probable NASH, with odds ratios (ORs) of 4.55 [95% confidence interval (CI) 3.16, 6.55] and 5.28 (95% CI 3.94, 7.09), respectively, comparing quartile 4 with quartile 1 (both p for trend <0.001). However, C‐peptide quartiles were negatively associated with the probable presence of advanced fibrosis (Q4 vs. Q1, OR 0.59, 95% CI 0.36, 0.97, p for trend <0.05). A 1‐SD increment of ln(C‐peptide) was also significantly associated with inflammatory and fibrotic progression (OR 1.34, 95% CI 1.27, 1.41; OR 0.88, 95% CI 0.79, 0.98, respectively).
Conclusions
Significant but opposite associations between C‐peptide and inflammatory and fibrotic progression of NAFLD were observed. Understanding islet hormone changes during type 2 diabetes and differentiating the stage of NAFLD may help to personalize treatment strategies for NAFLD patients with type 2 diabetes.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31351021</pmid><doi>10.1002/dmrr.3210</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-5117-1614</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-7552 |
| ispartof | Diabetes/metabolism research and reviews, 2020-02, Vol.36 (2), p.e3210-n/a |
| issn | 1520-7552 1520-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2265762597 |
| source | Access via Wiley Online Library |
| subjects | advanced fibrosis C‐peptide Diabetes Diabetes mellitus (non-insulin dependent) Fatty liver Fibrosis Inflammation Liver diseases Metabolic syndrome nonalcoholic fatty liver disease Peptides Steatosis type 2 diabetes mellitus Ultrasound |
| title | C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A31%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C%E2%80%90peptide%20is%20associated%20with%20NAFLD%20inflammatory%20and%20fibrotic%20progression%20in%20type%202%20diabetes&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Wang,%20Ningjian&rft.date=2020-02&rft.volume=36&rft.issue=2&rft.spage=e3210&rft.epage=n/a&rft.pages=e3210-n/a&rft.issn=1520-7552&rft.eissn=1520-7560&rft_id=info:doi/10.1002/dmrr.3210&rft_dat=%3Cproquest_cross%3E2350162368%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350162368&rft_id=info:pmid/31351021&rfr_iscdi=true |